| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT06917911 Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment… |
Trial sites expanded: 7 -> 14 locations |
| 2026-06-12 | NCT07198074 Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin… |
Trial sites expanded: 206 -> 211 locations |
| 2026-06-12 | NCT07061977 Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation… |
Trial sites expanded: 253 -> 260 locations |
| 2026-06-12 | NCT05691491 Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their… |
Enrollment reduced: 58 -> 42 participants |
| 2026-06-12 | NCT04190550 Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments… |
date change Primary completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-12 | NCT04190550 Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments… |
date change Completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-12 | NCT05588453 Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of… |
Enrollment reduced: 30 -> 24 participants |
| 2026-06-12 | NCT05588453 Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of… |
date change Primary completion pushed: 2026-04-15 -> 2027-04-15 |
| 2026-06-12 | NCT05588453 Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of… |
date change Completion pushed: 2026-04-15 -> 2027-04-15 |
| 2026-06-12 | NCT03907475 Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid… |
date change Primary completion pushed: 2026-06-01 -> 2027-06-01 |
| 2026-06-12 | NCT03907475 Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid… |
date change Completion pushed: 2026-06-01 -> 2027-06-01 |
| 2026-06-12 | NCT03983824 Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone… |
date change Primary completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-12 | NCT03983824 Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone… |
date change Completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-12 | NCT05886049 A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and… |
Primary endpoint(s) modified |
| 2026-06-12 | NCT05886049 A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and… |
Enrollment increased: 28 -> 38 participants |
| 2026-06-12 | NCT04491942 Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy… |
date change Primary completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-12 | NCT04491942 Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy… |
date change Completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-11 | NCT04332367 Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or… |
date change Primary completion pushed: 2026-04 -> 2026-09-30 |
| 2026-06-11 | NCT04332367 Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or… |
date change Completion pushed: 2026-04 -> 2026-09-30 |
| 2026-06-11 | NCT07015242 A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line… |
Trial sites reduced: 82 -> 40 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-11 | NCT07642024 A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients… | Phase 2/3 | Not Yet Recruiting |
| 2026-06-11 | NCT07643103 Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative… | Phase 2 | Not Yet Recruiting |
| 2026-06-10 | NCT07639528 Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted… | Phase 2 | Not Yet Recruiting |
| 2026-06-10 | NCT07640048 Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study | Recruiting | |
| 2026-06-09 | NCT07636564 Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute… | Phase 2 | Not Yet Recruiting |
| 2026-06-08 | NCT07634094 Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and… | Phase 2 | Not Yet Recruiting |
| 2026-06-04 | NCT07628062 Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal… | Phase 2 | Not Yet Recruiting |
| 2026-06-03 | NCT07622186 A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer… | Phase 2 | Not Yet Recruiting |
| 2026-06-03 | NCT07622797 Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as… | Phase 2 | Recruiting |
| 2026-06-03 | NCT07623356 A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell… | Phase 1/2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06457503 | A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With… | Nasopharyngeal Cancer Recurrent | Recruiting |
| NCT06289673 | Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute… | Acute Lymphoblastic Leukemia | Recruiting |
| NCT05689671 | Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung… | Non-Small Cell Lung Cancer Metastatic | Active, Not Recruiting |
| NCT07619235 | A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination… | Biliary Tract Cancer (BTC) | Not Yet Recruiting |
| Phase 3 | |||
| NCT06899126 | Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in… | Non-small Cell Lung Cancer | Recruiting |
| NCT07340515 | Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial | Nasopharyngeal Carcinoma (NPC) | Recruiting |
| NCT06470243 | Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will… | Castration-Resistant Prostate Carcinoma | Recruiting |
| NCT07229625 | A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing… | Advanced Biliary Tract Cancer | Recruiting |
| NCT04339218 | Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in… | Lung Adenocarcinoma | Recruiting |
| NCT07196774 | A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in… | Early-stage or Locally Advanced HER2-positive Breast Cancer | Recruiting |
| NCT06711900 | A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination… | Non-Small Cell Lung Cancer | Recruiting |
| NCT06956001 | Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With… | EGFR | Recruiting |
| NCT06970639 | A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus… | NSCLC Patients With Brain Metastasis | Recruiting |
| NCT05827523 | Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS /… | Ovarian Cancer | Recruiting |
| NCT03126916 | Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With… | Ganglioneuroblastoma | Recruiting |
| NCT07026474 | Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally… | Recurrent Head and Neck Squamous Cell Carcinoma | Recruiting |
| NCT07132684 | Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia… | AML, Adult | Recruiting |
| NCT06239727 | Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment… | Nasopharyngeal Carcinoma | Recruiting |
| NCT06687369 | A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12… | Non Squamous Non Small Cell Lung Cancer | Recruiting |
| NCT07459296 | Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC | Nasopharyngeal Carcinoma (NPC) | Recruiting |
| NCT07463651 | MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib | Acute Myeloid Leukemia (AML) | Recruiting |
| NCT07125755 | Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant… | Squamous Cell Cancer of Head and Neck (SCCHN) | Recruiting |
| NCT06744504 | Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid… | AML | Recruiting |
| NCT06388733 | A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed… | Glioblastoma | Recruiting |
| NCT07223814 | Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by… | Acute Myeloid Leukemia | Recruiting |